Study On Correlation Between TCM Pathogenic Syndrome Of Advanced Non-small Cell Lung Cancer And Short-term Therapeutic Effect Of Anrotinib

Objectives To study the distribution of TCM syndromes in patients with advanced nonsmall cell lung cancer(NSCLC)and explore its correlation with the short-term efficacy of anrotinib in the treatment of advanced non-small cell lung cancer Methods From January 2019 to November 2019,168 outpatients and inpatients with advanced NSCLC were selected from the Department of Oncology of the People's Hospital of Tangshan City,Hebei Province,and the clinical information of the patients' age,gender,smoking,PS score,stage,and pathological type was collected.Refer to Zhu Wenfeng's "Differentiation of Syndrome Differentiation" to identify the pathogenic syndrome of each selected patient.After 2 cycles of treatment with anlotinib,the clinical efficacy was evaluated.The logistic regression method was used to analyze the syndromes of traditional Chinese medicine(qi deficiency,phlegm,yin deficiency,blood stasis,heat,dampness,stagnation)and age,Gender,whether to smoke,PS score,TNM stage,pathological type,etc.and the recent efficacy of anlotinib.Results 1.In this study,a total of 168 patients were selected,13 patients fell off,and 155 patients with advanced NSCLC completed the trial.The age range is 39?75 years old,with an average age of(62.07 ± 8.213)years;there are 125 male patients(accounting for 80.65%),30 female patients(accounting for 19.35%);smoking patients There were 113 cases(72.90%)and 42 cases of non-smokers(27.10%);there were 34 cases(21.94%)and 57 cases(36.77%)of patients with PS scores of 0,1 and 2 respectively.)And 64 cases(41.29%);56 cases(36.13%)of stage IIIB stage TNM,99 cases(63.87%)of stage IV patients;95 cases(61.29)of patients with pathological type of squamous cell carcinoma %),42 patients with pathological type of adenocarcinoma(27.10%),18 patients with other types(11.61%).2 TCM pathogenic syndrome: 99 cases of Qi deficiency(63.87%),94 cases of sputum(60.65%),82 cases of Yin deficiency(52.90%),61 cases of blood stasis(39.35%),48 cases of fever(accounting for 30.97%),wet in 45 cases(29.03%),stagnation in 38 cases(24.52%),other 5 cases(3.23%),etc.3 After 2 cycles of anrotinib treatment,there were 0 cases of complete remission(accounting for 0.00%),41 cases of partial remission(accounting for 26.45%),82 cases of stable disease(52.90%),and 32 cases of disease progression(Accounting for 20.65),the objective response rate was 26.45%,and the disease control rate was 79.35%.4 The results of single factor analysis affecting the efficacy of anlotinib showed that the general clinical factors PS score,pathological type,pathogenic syndrome phlegm,Qi deficiency,Yin deficiency is related to the patient's short-term efficacy(P < 0.05).5 Binary Logistic regression analysis of the pathogenic syndrome of traditional Chinese medicine affecting the efficacy of anrotinib,the results showed that it had qi deficiency(OR = 1.711,95% CI = 1.040-2.815,P = 0.034)and yin deficiency(OR = 2.384,95 % CI = 1.438-3.953,P = 0.001)Patients with pathogenic syndrome have relatively poor efficacy,and patients with sputum(OR = 0.439,95% CI = 0.264-0.731,P = 0.002)have relatively poor efficacy better.6 The results of multi-factor analysis affecting the efficacy of anlotinib showed that with PD as the reference category,the PS score was 0 points(OR = 8.017,95% CI = 1.680-38.268,P = 0.009)and 1 point(OR = 4.430,95% CI = 1.182-16.596,P = 0.027),pathological type of squamous cell carcinoma(OR = 7.785,95% CI = 1.349-44.933,P = 0.022),with phlegm syndrome(OR = 0.122,95% CI = 0.035-0.421,P = 0.001),patients with advanced NSCLC without yin deficiency syndrome(OR = 4.627,95% CI = 1.267-16.891,P = 0.020)have good PR efficacy;pathological type is squamous cell carcinoma(OR = 5.843,95% CI = 1.481-23.045,P = 0.012),with phlegm syndrome(OR = 0.144,95% CI = 0.038-0.341,P = 0.000),without yin deficiency syndrome(OR = 3.955,95% CI = 1.215-12.873,P = 0.0222)patients with advanced NSCLC have good SD effect.Conclusions 1.According to statistical results,the pathogenic syndromes of 155 patients with advanced NSCLC are mainly Qi deficiency,phlegm,Yin deficiency,blood stasis,heat,dampness,and stagnation;2.The factors that affect the short-term efficacy of anrotinib in the treatment of patients with advanced NSCLC include phlegm syndrome,yin deficiency syndrome,PS score,pathological type,and the influencing factors of different efficacy are different;3.Application of anrotinib in the treatment of patients with advanced NSCLC with phlegm syndrome and yin deficiency syndrome is relatively effective.Figure0;Table16;Reference 228...